Spring 2022 After lonely labwork and distancing during the pandemic winter, we are looking forward to spring and freely shared and fun immunology. From left: Taissa, Hanne, Elias, and Kjell-Rune.
Kick-Off Fall 2019 We are saving the world one Escape room at the time. Here, we prevented a massive bioterror attack to be launched from Oslo in just 47 minutes.
Alirezaylavasani A, Egner IM, Dahl B, Chopra A, de Matos Kasahara T, Goll GL, Jahnsen J, Grødeland G, Vaage JT, Lund-Johansen F, Holter JC, Halvorsen B, Jørgensen KK, Munthe LA, Kared H (2024) Deficient SARS-CoV-2 hybrid immunity during inflammatory bowel disease Clin Immunol, 271, 110404 (in press) DOI 10.1016/j.clim.2024.110404, PubMed 39645159 Ørbo HS, de Matos Kasahara T, Wolf AS, Bjørlykke KH, Sexton J, Jyssum I, Tveter AT, Solum G, Kjønstad IF, Bhandari S, Christensen IE, Kvien TK, Lind A, Kared H, Jahnsen J, Haavardsholm EA, Munthe LA, Provan SA, Vaage JT, Mjaaland S, Syversen SW, Jørgensen KK, Grødeland G, Goll GL (2024) Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumour necrosis factor inhibitors: a prospective cohort study Lancet Reg Health Eur, 48, 101121 DOI 10.1016/j.lanepe.2024.101121, PubMed 39624496 Wolf AS, Bjørlykke KH, Ørbo HS, Bhandari S, Solum G, Kjønstad IF, Jyssum I, Nygaard UC, Kristoffersen AB, Christensen IE, Josefsson SE, Lund KP, Chopra A, Osen JR, Chaban V, Tveter AT, Sexton J, Kvien TK, Jahnsen J, Haavardsholm EA, Grødeland G, Vaage JT, Provan SA, Kared H, Lund-Johansen F et al. (2024) T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study EBioMedicine, 108, 105317 DOI 10.1016/j.ebiom.2024.105317, PubMed 39260039